From Our Thought Leaders

Human-Centric AI: Accelerating Formulation Development Without Compromising Trust

As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerating timelines while safeguarding scientific rigor, patient safety, and regulatory trust. In thi... Read more

04 March, 2026 | Wednesday | Expert Opinion
Redefining CNS Therapeutics: A Conversation with Joel Latham on Incannex Healthcare’s Clinical Vision

    Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based therapeutics targeting significant unmet needs in sleep disorders, inflammatory disease, and anxiety... Read more

02 March, 2026 | Monday | Interaction
Designing Decarbonization: Embedding Sustainability at the Core of Life Sciences Infrastructure

As life sciences companies scale biologics, advanced therapies, and personalized medicines, sustainability has moved from aspiration to operational imperative. From decarbonizing complex global supply chains to embedding environmental governance into... Read more

02 March, 2026 | Monday | News
Integrated Partnerships for Enabling Agility in Biologics Development

As biologic modalities grow more complex and timelines compress, the operational relationship between contract development and manufacturing organizations (CDMOs) and their clients determines the program efficiency, outcome quality, and supply reliab... Read more

02 March, 2026 | Monday | Opinion

Bio Finance

Cure Rare Disease and LGMD2L Foundation Launch $7.65M Partnership to Advance ANO5 Gene Therapy

  Cure Rare Disease (CRD), a non-profit biotechnology organization, announced a landmark partnership with the LGMD2L Foundation. This collaboration is backed by a generous commitment of $7.65 million from the LGMD2L Foundation to develop a nove... Read more

04 March, 2026 | Wednesday | News
Altesa BioSciences Raises $75 Million Series B Led by Forbion to Advance First-in-Class Rhinovirus Therapy Vapendavir into Phase 2b

  -Financing led by Forbion, joined by Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners- -Proceeds to advance vapendavir, a first-in-class therapeutic for the treatment of rhinovirus, the predominant cause of respiratory e... Read more

23 February, 2026 | Monday | News

Contract Services

BioMed Realty Signs 15-Year Lease with CordenPharma Colorado for Purpose-Built Lab Facility at Flatiron Park

BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPharma Colorado, a leading peptide drug substance Contract Development and Manufacturing Organizat... Read more

06 March, 2026 | Friday | News
Former BioDuro Leadership Launches Forma Life Sciences as Independent CDMO

-Forma Life Sciences, Inc. announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product m... Read more

05 March, 2026 | Thursday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close